Know Labs, Inc., a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters’ option to purchase 1,987,500 warrants.
The Company raised gross proceeds of $3.445 million less the underwriting discounts and commissions and estimated Offering expenses payable by Know Labs. The Offering was conducted as part of Know Labs’ strategic plan to accelerate the development of its proprietary technology, which includes the KnowU™ wearable non-invasive continuous glucose monitoring device. The capital raised will be instrumental in advancing the Company’s ongoing clinical validation studies and product development efforts on the path toward FDA clearance, and in continuing to build a robust intellectual property moat surrounding Know Labs’ technology.